# Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

> **NCT00574379** · PHASE2 · COMPLETED · sponsor: **Faes Farma, S.A.** · enrollment: 805 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis
- Hay Fever
- Allergic Conjunctivitis
- Hypersensitivity

## Interventions

- **DRUG:** Bilastine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00574379
- **Lead sponsor:** Faes Farma, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00574379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00574379, "Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00574379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*